<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3631d351-4653-3512-e063-6394a90a81c0"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DEFERIPRONE TABLETS safely and effectively. See full prescribing information for DEFERIPRONE TABLETS.
 <br/>
      <br/>
DEFERIPRONE tablets, for oral use
 <br/>
Initial U.S. Approval: 2011
</title>
   <effectiveTime value="20250528"/>
   <setId root="5af1643d-4c6e-4668-ae9b-1046f0ad6d8a"/>
   <versionNumber value="16"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="146974886"/>
            <name>Sun Pharmaceutical Industries, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="600072078"/>
                        <name>Taro Pharmaceutical Industries, Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51672-4196" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51672-4237" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3632ad31-a79d-9e63-e063-6394a90a14cf"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250528"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="51672-4237" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Deferiprone</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Deferiprone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NPU9M2E6L8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLCELLULOSE (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C9H2L21V7U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDIUM-CHAIN TRIGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VH2XOU12IE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYDEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1000"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2BTY8KH53L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFERIPRONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2BTY8KH53L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFERIPRONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51672-4237-4" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240205"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA208800" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240205"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">T;1K</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="51672-4196" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Deferiprone</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Deferiprone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2BTY8KH53L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFERIPRONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2BTY8KH53L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFERIPRONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51672-4196-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240205"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA208800" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240205"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>White to Pinkish-White</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">T;5</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="3631d351-4654-3512-e063-6394a90a81c0"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: AGRANULOCYTOSIS AND NEUTROPENIA</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Deferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.
   
    <content styleCode="italics">[see
    
     <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
   
    </content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor regularly while on therapy.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Interrupt deferiprone therapy if neutropenia develops.
   
    <content styleCode="italics">[see
    
     <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
   
    </content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">Interrupt deferiprone if infection develops, and monitor the ANC more frequently.
   
    <content styleCode="italics">[see
    
     <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
   
    </content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">Advise patients taking deferiprone to report immediately any symptoms indicative of infection.
   
    <content styleCode="italics">[see
    
     <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
   
    </content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: AGRANULOCYTOSIS AND NEUTROPENIA</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Deferiprone can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis. (
   
      <linkHtml href="#S5.1">5.1</linkHtml>)
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Measure the absolute neutrophil count (ANC) before starting deferiprone and monitor regularly while on therapy. (
   
      <linkHtml href="#S5.1">5.1</linkHtml>)
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Interrupt deferiprone therapy if neutropenia develops. (
   
      <linkHtml href="#S5.1">5.1</linkHtml>)
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Interrupt deferiprone if infection develops and monitor the ANC more frequently. (
   
      <linkHtml href="#S5.1">5.1</linkHtml>)
  
     </content>
                           </item>
                           <item>
                              <content styleCode="bold">Advise patients taking deferiprone to report immediately any symptoms indicative of infection. (
   
      <linkHtml href="#S5.1">5.1</linkHtml>)
  
     </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="3631d351-4655-3512-e063-6394a90a81c0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate.</paragraph>
               </text>
               <effectiveTime value="20240101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Deferiprone tablets are an iron chelator indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. (
 
    <linkHtml href="#S1">1</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="3631d351-4656-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Chiesi USA, Inc.'s FERRIPROX
  
   <sup>®</sup>(deferiprone) tablets. However, due to Chiesi USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="3631d351-4657-3512-e063-6394a90a81c0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Deferiprone tablets are available in two formulations. A 1,000 mg formulation and a 500 mg formulation, which have different dosing regimens to achieve the same total daily dosage. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>)
 
    </item>
                           <item>To prevent medication errors, before prescribing and dispensing, ensure that the tablet formulation is appropriate for the dosing regimen. Each tablet has distinct identifying characteristics. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>,
  
     <linkHtml href="#S3">3</linkHtml>)
 
    </item>
                           <item>Deferiprone tablets (three times a day), 1,000 mg:
  
     <list listType="unordered" styleCode="Circle">
                                 <item>Starting oral dosage: 75 mg/kg/day (actual body weight) in three divided doses (
    
       <linkHtml href="#S2.3">2.3</linkHtml>)
   
      </item>
                                 <item>Maximum oral dosage: 99 mg/kg/day (actual body weight) in three divided doses (
    
       <linkHtml href="#S2.3">2.3</linkHtml>)
   
      </item>
                              </list>
                           </item>
                           <item>Deferiprone tablets (three times a day), 500 mg:
  
     <list listType="unordered" styleCode="Circle">
                                 <item>Starting oral dosage: 75 mg/kg/day (actual body weight) in three divided doses (
    
       <linkHtml href="#S2.4">2.4</linkHtml>)
   
      </item>
                                 <item>Maximum oral dosage: 99 mg/kg/day (actual body weight) in three divided doses (
    
       <linkHtml href="#S2.4">2.4</linkHtml>)
   
      </item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="3631d351-4658-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Dosage and Administration Information</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Deferiprone tablets are available in a 1,000 mg formulation and a 500 mg formulation, which have different oral dosing regimens to achieve the same total daily dosage.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Deferiprone tablets (three times a day) - 1,000 mg - given three times a day
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]
  
   </content>
                           </item>
                           <item>Deferiprone tablets - 500 mg - given three times a day
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]
  
   </content>
                           </item>
                        </list>
                        <paragraph>To prevent medication errors, before prescribing and dispensing, ensure that the tablet formulation is appropriate for the dosing regimen. Each tablet has distinct identifying characteristics
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S3">Dosage Forms and Strengths (3)</linkHtml>].
 
  </content>
                        </paragraph>
                        <paragraph>For patients who have trouble swallowing tablets, consider the use of oral solution (see the prescribing information for oral solution).</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-4659-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Monitoring for Safety</content>
                              </paragraph>
                              <paragraph>Due to the risk of agranulocytosis, monitor ANC before and during deferiprone therapy.</paragraph>
                              <paragraph>Test ANC prior to start of deferiprone therapy and monitor on the following schedule during treatment:</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>First six months of therapy: Monitor ANC weekly;</item>
                                 <item>Next six months of therapy: Monitor ANC once every two weeks;</item>
                                 <item>After one year of therapy: Monitor ANC every two to four weeks (or at the patient's blood transfusion interval in patients that have not experienced an interruption due to any decrease in ANC
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>.
 
  </item>
                              </list>
                              <paragraph>Due to the risk of hepatic transaminase elevations, monitor ALT before and monthly during deferiprone therapy
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
 
  </content>.

 </paragraph>
                              <paragraph>Due to the risk of zinc deficiency, monitor zinc levels before and regularly during deferiprone therapy
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="3631d351-465a-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage for 1,000 mg Deferiprone Tablets (three times a day) for Adult Patients with Transfusional Iron Overload due to Thalassemia Syndromes</title>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-465b-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Starting Dosage for Three Times a Day Tablets</content>
                              </paragraph>
                              <paragraph>The recommended starting oral dosage of deferiprone tablets (three times a day) is 75 mg/kg/day (actual body weight), in three divided doses per day. Table 3 describes the number of deferiprone tablets (three times a day) needed to achieve the 75 mg/kg/day total starting dosage). Round dose to the nearest 500 mg (half-tablet).</paragraph>
                              <table ID="table3" width="75%">
                                 <caption>Table 3: Number of Deferiprone 1,000 mg Tablets (three times a day) Needed to Achieve the Total Starting Daily Dosage of 75 mg/kg (rounded to the nearest half-tablet)</caption>
                                 <col width="30%" align="center" valign="top"/>
                                 <col width="23%" align="center" valign="middle"/>
                                 <col width="26%" align="center" valign="middle"/>
                                 <col width="21%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Body Weight 
     <br/>  (kg)
    </th>
                                       <th styleCode="Rrule">Morning</th>
                                       <th styleCode="Rrule">Midday</th>
                                       <th styleCode="Rrule">Evening</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">20</td>
                                       <td styleCode="Rrule">0.5</td>
                                       <td styleCode="Rrule">0.5</td>
                                       <td styleCode="Rrule">0.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">30</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">0.5</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">40</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">50</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">1.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">60</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">1.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">70</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">80</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">90</td>
                                       <td styleCode="Rrule">2.5</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2.5</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>To minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved.</paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3631d351-465c-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage Adjustments for Three Times Daily Tablets</content>
                              </paragraph>
                              <paragraph>Tailor dosage adjustments for deferiprone tablets (three times a day) to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden). The maximum oral dosage is 99 mg/kg/day (actual body weight), in three divided doses per day. Table 4 describes the number of deferiprone tablets (three times a day) needed to achieve the 99 mg/day total maximum daily dosage.</paragraph>
                              <table ID="table4" width="75%">
                                 <caption>Table 4: Number of Deferiprone 1,000 mg Tablets (three times a day) Needed to Achieve the Maximum Total Daily Dosage of 99 mg/kg (rounded to the nearest half-tablet)</caption>
                                 <col width="30%" align="center" valign="middle"/>
                                 <col width="23%" align="center" valign="middle"/>
                                 <col width="26%" align="center" valign="middle"/>
                                 <col width="21%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Body Weight 
     <br/>  (kg)
    </th>
                                       <th styleCode="Rrule">Morning</th>
                                       <th styleCode="Rrule">Midday</th>
                                       <th styleCode="Rrule">Evening</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">20</td>
                                       <td styleCode="Rrule">0.5</td>
                                       <td styleCode="Rrule">0.5</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">30</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">40</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">1.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">50</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">60</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">70</td>
                                       <td styleCode="Rrule">2.5</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">80</td>
                                       <td styleCode="Rrule">2.5</td>
                                       <td styleCode="Rrule">2.5</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">90</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="italics">Pediatric use information is approved for Chiesi USA, Inc.'s FERRIPROX® (deferiprone) tablets. However, due to Chiesi USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="3631d351-465d-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Recommended Dosage for 500 mg Deferiprone Tablets (three times a day) for Adult Patients with Transfusional Iron Overload due to Thalassemia Syndromes</title>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-465e-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Starting Dosage for Three Times a Day Tablets</content>
                              </paragraph>
                              <paragraph>The recommended starting oral dosage of deferiprone tablets (three times a day) is 75 mg/kg/day (actual body weight), in three divided doses per day. Table 5 describes the number of deferiprone tablets (three times a day) needed to achieve the 75 mg/kg/day total starting dosage. Round dose to the nearest 250 mg (half-tablet).</paragraph>
                              <table ID="table5" width="75%">
                                 <caption>Table 5: Number of Deferiprone 500 mg Tablets (three times a day) Needed to Achieve the Total Starting Daily Dosage of 75 mg/kg dose (rounded to the nearest half-tablet)</caption>
                                 <col width="30%" align="center" valign="middle"/>
                                 <col width="23%" align="center" valign="middle"/>
                                 <col width="26%" align="center" valign="middle"/>
                                 <col width="21%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Body Weight 
     <br/>  (kg)
    </th>
                                       <th styleCode="Rrule">Morning</th>
                                       <th styleCode="Rrule">Midday</th>
                                       <th styleCode="Rrule">Evening</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">20</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">30</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">1.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">40</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">50</td>
                                       <td styleCode="Rrule">2.5</td>
                                       <td styleCode="Rrule">2.5</td>
                                       <td styleCode="Rrule">2.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">60</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">70</td>
                                       <td styleCode="Rrule">3.5</td>
                                       <td styleCode="Rrule">3.5</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">80</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">90</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>To minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved.</paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3631d351-465f-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Dosage Adjustments</content>
                              </paragraph>
                              <paragraph>Tailor dosage adjustments for deferiprone tablets (three times a day) to the individual patient's response and therapeutic goals (maintenance or reduction of body iron burden). The maximum oral dosage is 99 mg/kg/day (actual body weight), in three divided doses per day. Table 6 describes the number of deferiprone tablets (three times a day) needed to achieve the 99 mg/day total maximum daily dosage.</paragraph>
                              <table ID="table6" width="75%">
                                 <caption>Table 6: Number of Deferiprone 500 mg Tablets (three times a day) Needed to Achieve the Maximum Total Daily Dosage of 99 mg/kg dose (rounded to the nearest half-tablet)</caption>
                                 <col width="30%" align="center" valign="middle"/>
                                 <col width="23%" align="center" valign="middle"/>
                                 <col width="26%" align="center" valign="middle"/>
                                 <col width="21%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Body Weight 
     <br/>  (kg)
    </th>
                                       <th styleCode="Rrule">Morning</th>
                                       <th styleCode="Rrule">Midday</th>
                                       <th styleCode="Rrule">Evening</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">20</td>
                                       <td styleCode="Rrule">1.5</td>
                                       <td styleCode="Rrule">1</td>
                                       <td styleCode="Rrule">1.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">30</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">40</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">2</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">50</td>
                                       <td styleCode="Rrule">3.5</td>
                                       <td styleCode="Rrule">3</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">60</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">4</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">70</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">4.5</td>
                                       <td styleCode="Rrule">4.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">80</td>
                                       <td styleCode="Rrule">5.5</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">5.5</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">90</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">6</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>
                                 <content styleCode="italics">Pediatric use information is approved for Chiesi USA, Inc.'s FERRIPROX® (deferiprone) tablets. However, due to Chiesi USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="3631d351-4660-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Monitoring Ferritin Levels to Assess Efficacy</title>
                     <text>
                        <paragraph>Monitor serum ferritin concentration every two to three months to assess the effect of deferiprone on body iron stores. If the serum ferritin is consistently below 500 mcg/L, consider temporarily interrupting deferiprone therapy until serum ferritin rises above 500 mcg/L.</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="3631d351-4661-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Modification for Drug Interactions</title>
                     <text>
                        <paragraph>Allow at least a 4-hour interval between administration of deferiprone and other drugs or supplements containing polyvalent cations such as iron, aluminum, or zinc
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>,
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="3631d351-4662-3512-e063-6394a90a81c0"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Tablets (three times a day): 1,000 mg are white, film-coated, oval shaped tablets; imprinted with "T" score "1 K" on one side and plain on the other side.</item>
                     <item>Tablets: 500 mg are white to pinkish-white, capsule-shaped tablets; scored on one side, engraved "T" on the left of the score line and "5" on the right and plain on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20230831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tablets (three times a day): 1,000 mg with functional scoring (
  
     <linkHtml href="#S3">3</linkHtml>)
 
    </item>
                           <item>Tablets (three times a day): 500 mg with functional scoring (
  
     <linkHtml href="#S3">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="3631d351-4663-3512-e063-6394a90a81c0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Deferiprone is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulations. The following reactions have been reported in association with the administration of deferiprone: Henoch-Schönlein purpura; urticaria; and periorbital edema with skin rash
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>].
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20230831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to deferiprone or to any of the excipients in the formulations. (
 
    <linkHtml href="#S4">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="3631d351-4664-3512-e063-6394a90a81c0"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Liver Enzyme Elevations: Monitor monthly and discontinue for persistent elevations. (
  
     <linkHtml href="#S5.2">5.2</linkHtml>)
 
    </item>
                           <item>Zinc Deficiency: Monitor during therapy and supplement for deficiency. (
  
     <linkHtml href="#S5.3">5.3</linkHtml>)
 
    </item>
                           <item>Embryo-Fetal Toxicity: Can cause fetal harm. (
  
     <linkHtml href="#S5.4">5.4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="3631d351-4665-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Agranulocytosis and Neutropenia</title>
                     <text>
                        <paragraph>Fatal agranulocytosis can occur with deferiprone use. Deferiprone can also cause neutropenia, which may foreshadow agranulocytosis. Measure the absolute neutrophil count (ANC) before starting deferiprone therapy and monitor it regularly while on therapy
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Reduction in the frequency of ANC monitoring should be considered on an individual patient basis, according to the health care provider's assessment of the patient's understanding of the risk minimization measures required during therapy.</paragraph>
                        <paragraph>Interrupt deferiprone therapy if neutropenia develops (ANC &lt; 1.5 × 10
 
  <sup>9</sup>/L).

 </paragraph>
                        <paragraph>Interrupt deferiprone if infection develops and monitor the ANC frequently.</paragraph>
                        <paragraph>Advise patients taking deferiprone to immediately interrupt therapy and report to their physician if they experience any symptoms indicative of infection.</paragraph>
                        <paragraph>The incidence of agranulocytosis was 1% of patients in pooled clinical trials of 642 patients with thalassemia syndromes. The mechanism of deferiprone-associated agranulocytosis is unknown. Agranulocytosis and neutropenia usually resolve upon discontinuation of deferiprone, but there have been reports of agranulocytosis leading to death.</paragraph>
                        <paragraph>Implement a plan to monitor for and to manage agranulocytosis and neutropenia prior to initiating deferiprone treatment.</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section ID="id_link_357ceb22-15f1-165b-e063-6294a90a7193">
                           <id root="36324890-7f07-8e08-e063-6294a90a330a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">For agranulocytosis (ANC &lt; 0.2 × 10 
   <sup>9</sup> /L) and severe neutropenia (0.2 x 10 
   <sup>9</sup>/L ≤ ANC &lt; 0.5 x 10 
   <sup>9</sup>/L): 
  </content>
                              </paragraph>
                              <paragraph>Consider hospitalization and other management as clinically appropriate.</paragraph>
                              <paragraph>Do not resume deferiprone in patients who have developed agranulocytosis unless potential benefits outweigh potential risks. Do not rechallenge patients who have developed neutropenia with deferiprone unless potential benefits outweigh potential risks.</paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                     <component>
                        <section ID="id_link_357cfe4e-f647-3bba-e063-6294a90a0c90">
                           <id root="3631d351-4667-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">For neutropenia (ANC &lt; 1.5 × 10
  
   <sup>9</sup>/L and ≥ 0.5 × 10
  
   <sup>9</sup>/L):
 
  </content>
                              </paragraph>
                              <paragraph>Instruct the patient to immediately discontinue deferiprone and all other medications with a potential to cause neutropenia.</paragraph>
                              <paragraph>Obtain a complete blood cell (CBC) count, including a white blood cell (WBC) count corrected for the presence of nucleated red blood cells, an absolute neutrophil count (ANC), and a platelet count daily until recovery (ANC ≥ 1.5 × 10
 
  <sup>9</sup>/L).

 </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="3631d351-4668-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Liver Enzyme Elevations</title>
                     <text>
                        <paragraph>In pooled clinical trials, 7.5% of 642 patients with thalassemia syndromes treated with deferiprone developed increased ALT values. Four (0.62%) deferiprone-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST.</paragraph>
                        <paragraph>Monitor serum ALT values monthly during therapy with deferiprone and consider interruption of therapy if there is a persistent increase in the serum transaminase levels
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="3631d351-4669-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Zinc Deficiency</title>
                     <text>
                        <paragraph>Decreased plasma zinc concentrations have been observed on deferiprone therapy. Monitor plasma zinc annually, and supplement in the event of a deficiency
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="3631d351-466a-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings from animal reproduction studies and evidence of genotoxicity, deferiprone can cause fetal harm when administered to a pregnant woman. The available data on the use of deferiprone in pregnant women are insufficient to inform risk. In animal studies, administration of deferiprone during the period of organogenesis resulted in embryo-fetal death and malformations at doses lower than equivalent human clinical doses. Advise pregnant women and females of reproductive potential of the potential risk to the fetus
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Advise females of reproductive potential to use an effective method of contraception during treatment with deferiprone and for at least six months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with deferiprone and for at least three months after the last dose
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>,
  
   <linkHtml href="#S8.3">8.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="3631d351-466b-3512-e063-6394a90a81c0"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described below and elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Agranulocytosis and Neutropenia
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Liver Enzyme Elevations
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                     <item>Zinc Deficiency
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions in patients with thalassemia (incidence &gt; 6%) are nausea, vomiting, abdominal pain, arthralgia, ALT increased and neutropenia. (5.1, 6)</paragraph>
                        <paragraph/>
                        <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc., at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</paragraph>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="3631d351-466c-3512-e063-6394a90a81c0"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The following adverse reaction information represents the pooled data collected from single arm or active-controlled clinical trials with deferiprone tablets (three times a day).</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section ID="id_link_357d0e7f-84ba-5e1a-e063-6294a90afb47">
                           <id root="3631d351-466d-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Thalassemia Syndromes</content>
                              </paragraph>
                              <paragraph>The safety of deferiprone was evaluated in the pooled clinical trial database
 
  <content styleCode="italics">[see Clinical Studies (14.1)]</content>. Patients received deferiprone tablets (three times a day). Deferiprone was administered orally three times a day (total daily dose either 50, 75, or 99 mg/kg), N=642. Among 642 patients receiving deferiprone, 492 (76.6%) were exposed for 6 months or longer and 365 (56.9%) were exposed for greater than one year.

 </paragraph>
                              <paragraph>The median age of patients who received deferiprone was 19 years (range 1, 77 years); 50.2% female; 71.2% White, 17.8% Asian, 9.2% Unknown, 1.2% Multi-racial and 0.6% Black.</paragraph>
                              <paragraph>The most serious adverse reaction reported in clinical trials with deferiprone was agranulocytosis
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
                              <paragraph>The most common adverse reactions (≥6%) reported during clinical trials were nausea, vomiting, abdominal pain, arthralgia, alanine aminotransferase increased and neutropenia.</paragraph>
                              <paragraph>The table below lists the adverse drug reactions that occurred in at least 1% of patients treated with deferiprone in clinical trials in patients with thalassemia syndromes.</paragraph>
                              <table width="90%" ID="table7">
                                 <caption>Table 7: Adverse reactions occurring in ≥ 1% of deferiprone-treated patients with thalassemia syndromes</caption>
                                 <col align="left" valign="top" width="70%"/>
                                 <col align="left" valign="top" width="30%"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Body System</th>
                                       <th styleCode="Rrule">(N=642)</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                       <th styleCode="Rrule">% Patients</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td colspan="2" styleCode="Lrule Rrule">
                                          <content styleCode="bold">BLOOD AND LYMPHATIC SYSTEM DISORDERS</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Neutropenia*</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Agranulocytosis
    
     <sup>†</sup>
                                       </td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr>
                                       <td colspan="2" styleCode="Lrule Rrule">
                                          <content styleCode="bold">GASTROINTESTINAL DISORDERS</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">13</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Abdominal pain/discomfort</td>
                                       <td styleCode="Rrule">10</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">10</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Dyspepsia</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr>
                                       <td colspan="2" styleCode="Lrule Rrule">
                                          <content styleCode="bold">INVESTIGATIONS</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Alanine aminotransferase increased</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Weight increased</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Aspartate aminotransferase increased</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr>
                                       <td colspan="2" styleCode="Lrule Rrule">
                                          <content styleCode="bold">METABOLISM AND NUTRITION DISORDERS</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Increased appetite</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Decreased appetite</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr>
                                       <td colspan="2" styleCode="Lrule Rrule">
                                          <content styleCode="bold">MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Arthralgia</td>
                                       <td styleCode="Rrule">10</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Back pain</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Pain in extremity</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Arthropathy</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr>
                                       <td colspan="2" styleCode="Lrule Rrule">
                                          <content styleCode="bold">NERVOUS SYSTEM DISORDERS</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>*Neutropenia includes events of severe neutropenia (ANC ≥0.2 x 10
 
  <sup>9</sup>/L and &lt;0.5 x 10
 
  <sup>9</sup>/L).

 </paragraph>
                              <paragraph>†Agranulocytosis (ANC&lt; 0.2 x 10
 
  <sup>9</sup>/L)

 </paragraph>
                              <paragraph/>
                              <paragraph>Gastrointestinal symptoms such as nausea, vomiting, and abdominal pain were the most frequent adverse reactions reported by patients participating in clinical trials and led to the discontinuation of deferiprone therapy in 1.6% of patients.</paragraph>
                              <paragraph>Chromaturia (reddish/brown discoloration of the urine) is a result of the excretion of iron in the urine.</paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="3631d351-466e-3512-e063-6394a90a81c0"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following additional adverse reactions have been reported in patients receiving deferiprone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and lymphatic system disorders:</content>thrombocytosis, pancytopenia.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac disorders:</content>atrial fibrillation, cardiac failure.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Congenital, familial and genetic disorders:</content>hypospadias.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye disorders:</content>diplopia, papilledema, retinal toxicity.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal disorders:</content>enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">General disorders and administration site conditions:</content>chills, edema peripheral, multi-organ failure.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary disorders:</content>jaundice, hepatomegaly.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorders:</content>anaphylactic shock, hypersensitivity.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and infestations:</content>cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations:</content>blood bilirubin increased, blood creatinine phosphokinase increased.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and nutrition disorders:</content>metabolic acidosis, dehydration.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and connective tissue disorders:</content>myositis, chondropathy, trismus.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system disorders:</content>cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric disorders:</content>bruxism, depression, obsessive-compulsive disorder.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal disorders:</content>glycosuria, hemoglobinuria.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, thoracic and mediastinal disorders:</content>acute respiratory distress syndrome, epistaxis, hemoptysis, pulmonary embolism.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin, subcutaneous tissue disorders:</content>hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schönlein purpura.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular disorders:</content>hypotension, hypertension.

 </paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="3631d351-466f-3512-e063-6394a90a81c0"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20230831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Drugs Associated with Neutropenia or Agranulocytosis: Avoid co-administration. If co-administration is unavoidable, closely monitor the absolute neutrophil count. (
  
     <linkHtml href="#S7.1">7.1</linkHtml>)
 
    </item>
                           <item>UGT1A6 Inhibitors: Avoid co-administration. (
  
     <linkHtml href="#S7.2">7.2</linkHtml>)
 
    </item>
                           <item>Polyvalent Cations: Allow at least a 4-hour interval between administration of deferiprone and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc). (
  
     <linkHtml href="#S2.6">2.6</linkHtml>,
  
     <linkHtml href="#S7.2">7.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="3631d351-4670-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Drugs Associated with Neutropenia or Agranulocytosis</title>
                     <text>
                        <paragraph>Avoid co-administration of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis. If co-administration is unavoidable, closely monitor the absolute neutrophil count
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="3631d351-4671-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Effect of Other Drugs on Deferiprone</title>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-4672-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">UDP-Glucuronosyltransferases (UGT)</content>
                              </paragraph>
                              <paragraph>Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with deferiprone
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>,
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>,
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3631d351-4673-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Polyvalent Cations</content>
                              </paragraph>
                              <paragraph>Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between deferiprone and other medications (e.g., antacids), or supplements containing these polyvalent cations
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="3631d351-4674-3512-e063-6394a90a81c0"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20230831"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Advise not to breastfeed. (
 
    <linkHtml href="#S8.2">8.2</linkHtml>) 
    <br/>   

   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Chiesi USA, Inc.'s FERRIPROX® (deferiprone) tablets. However, due to Chiesi USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="3631d351-4675-3512-e063-6394a90a81c0"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-4676-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>In animal reproduction studies, oral administration of deferiprone to pregnant rats and rabbits during organogenesis at doses 33% and 49%, respectively, of the maximum recommended human dose (MRHD) resulted in structural abnormalities, embryo-fetal mortality and alterations to growth
 
  <content styleCode="italics">(see
  
   <linkHtml href="#Data">Data</linkHtml>)
 
  </content>. The limited available data from deferiprone use in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriage. Based on evidence and developmental toxicity in animal studies, deferiprone can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.

 </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes
 
  <content styleCode="italics">.</content>In the U.S. general population, the estimated background risk of major birth defects and of miscarriage is 2 to 4% and 15 to 20%, respectively.

 </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="3631d351-4677-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                           <component>
                              <section>
                                 <id root="3631d351-4678-3512-e063-6394a90a81c0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>Post-marketing data available from 39 pregnancies of deferiprone-treated patients and 10 pregnancies of partners of deferiprone-treated patients are as follows:</paragraph>
                                    <paragraph>Of the 39 pregnancies in deferiprone-treated patients, 23 resulted in healthy newborns, 6 ended in spontaneous abortion, 9 had unknown outcomes, and 1 infant was born with anal atresia, nephroptosis, ventricular septal defect, hemivertebra and urethral fistula.</paragraph>
                                    <paragraph>Of the 10 pregnancies in partners of deferiprone-treated patients, 5 resulted in healthy newborns, 1 resulted in a healthy newborn with slight hypospadias, 1 was electively terminated, 1 resulted in the intrauterine death of twins, and 2 had unknown outcomes.</paragraph>
                                 </text>
                                 <effectiveTime value="20230831"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3631d351-4679-3512-e063-6394a90a81c0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>During organogenesis, pregnant rats and rabbits received deferiprone at oral doses of 0, 30, 80 or 200 mg/kg/day, and 0, 10, 50, or 150 mg/kg/day, respectively. The daily dose was administered as two equal divided doses approximately 7 hours apart. Doses of 200 mg/kg/day in rats and 150 mg/kg/day in rabbits, approximately 33% and 49% of the MRHD, respectively, resulted in increased post-implantation loss and reduced fetal weights in the presence of maternal toxicity (reduced maternal body weight and body weight gain in both rats and rabbits; abnormal large placenta at low incidence in rats). The 200 mg/kg/day dose in rats resulted in external, visceral and skeletal fetal malformations such as cranial malformations, cleft palate, limb malrotation, anal atresia, internal hydrocephaly, anophthalmia and fused bones. The dose of 150 mg/kg/day in rabbits resulted in external fetal malformations (partially opened eyes) and minor blood vessel and skeletal variations.</paragraph>
                                    <paragraph>In rats, malformations including micrognathia and persistent ductus arteriosus could be observed in the absence of maternal toxicity at doses equal to or greater than 30 and 80 mg/kg/day, approximately 5% and 13% of the MHRD, respectively.</paragraph>
                                 </text>
                                 <effectiveTime value="20230831"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="3631d351-467a-3512-e063-6394a90a81c0"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-467b-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of deferiprone in human milk, the effects on the breastfed child, or the effects on milk production.</paragraph>
                              <paragraph>Because of the potential for serious adverse reactions in the breastfed child, including the potential for tumorigenicity shown for deferiprone in animal studies, advise patients that breastfeeding is not recommended during treatment with deferiprone, and for at least 2 weeks after the last dose.</paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="3631d351-467c-3512-e063-6394a90a81c0"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-467d-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Pregnancy testing is recommended for females of reproductive potential prior to initiating deferiprone.</paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3631d351-467e-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                           <component>
                              <section>
                                 <id root="3631d351-467f-3512-e063-6394a90a81c0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Deferiprone can cause embryo-fetal harm when administered to a pregnant woman
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]
 
  </content>. Advise female patients of reproductive potential to use effective contraception during treatment with deferiprone and for at least 6 months after the last dose.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230831"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3631d351-4680-3512-e063-6394a90a81c0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with deferiprone and for at least 3 months after the last dose
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230831"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="3631d351-4681-3512-e063-6394a90a81c0"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of deferiprone tablets have not been established in pediatric patients with chronic iron overload due to blood transfusions who are less than 8 years of age.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Chiesi USA, Inc.'s FERRIPROX® (deferiprone) tablets. However, due to Chiesi USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="3631d351-4682-3512-e063-6394a90a81c0"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of deferiprone did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="3631d351-4683-3512-e063-6394a90a81c0"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>No cases of acute overdose have been reported. There is no specific antidote to deferiprone overdose.</paragraph>
                  <paragraph>Neurological disorders such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, hand movements and axial hypotonia have been observed in children treated with 2.5 to 3 times the recommended dose for more than one year. The neurological disorders progressively regressed after deferiprone discontinuation.</paragraph>
               </text>
               <effectiveTime value="20230831"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="3631d351-4684-3512-e063-6394a90a81c0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Deferiprone Tablets contain 1,000 mg or 500 mg deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a synthetic, orally active, iron-chelating agent. The molecular formula for deferiprone is C
 
  <sub>7</sub>H
 
  <sub>9</sub>NO
 
  <sub>2</sub>and its molecular weight is 139.15 g/mol. Deferiprone has the following structural formula:

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Deferiprone is a white to pinkish-white powder. It is sparingly soluble in deionized water (14.3 mg/mL) and has a melting point range of 272°C to 278°C.</paragraph>
               </text>
               <effectiveTime value="20230831"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="deferiprone-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section>
                     <id root="3631d351-4685-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Deferiprone Tablets (three times a day), 1,000 mg</content>
                        </paragraph>
                        <paragraph>White, film-coated, oval shaped tablets; imprinted with "T" score "1 K" on one side and plain on the other. The tablets can be broken in half along the score line. Each tablet contains 1,000 mg deferiprone and the following inactive ingredients: Tablet core - crospovidone, magnesium stearate and methylcellulose; Coating - copovidone, hypromellose, medium chain triglycerides, polydextrose, polyethylene glycol and titanium dioxide.</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3631d351-4686-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Deferiprone Tablets 500 mg</content>
                        </paragraph>
                        <paragraph>White to pinkish-white, capsule-shaped tablets; scored on one side, engraved "T" on the left of the score line and "5" on the right and plain on the other side. The tablets can be broken in half along the score line. Each tablet contains 500 mg deferiprone and the following inactive ingredients: Tablet core - colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose.</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="3631d351-4687-3512-e063-6394a90a81c0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230831"/>
               <component>
                  <section ID="S12.1">
                     <id root="3631d351-4688-3512-e063-6394a90a81c0"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Deferiprone is a chelating agent with an affinity for ferric ions (iron III). Deferiprone binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable at physiological pH.</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="3631d351-4689-3512-e063-6394a90a81c0"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>No clinical studies were performed to assess the relationship between the dose of deferiprone and the amount of iron eliminated from the body.</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-468a-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>At the maximum approved recommended dose, deferiprone does not prolong the QT interval to any clinically relevant extent.</paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="3631d351-468b-3512-e063-6394a90a81c0"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-468c-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Deferiprone Tablets (three times a day), 1,000 mg and 500 mg</content>
                              </paragraph>
                              <paragraph>The mean C
 
  <sub>max</sub>and AUC of deferiprone was 20 mcg/mL and 50 mcg∙h/mL, respectively, in healthy subjects. The dose proportionality of deferiprone over the approved recommended dosage range is unknown.

 </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3631d351-468d-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Absorption</paragraph>
                              <paragraph>Deferiprone appeared in the blood within 5 to 10 minutes after oral administration. Peak serum concentration of deferiprone was reached approximately 1 to 2 hours after a single dose.</paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                           <component>
                              <section>
                                 <id root="3631d351-468e-3512-e063-6394a90a81c0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">
                                          <content styleCode="underline">Effect of Food</content>
                                       </content>
                                    </paragraph>
                                    <paragraph>No clinically significant differences in the pharmacokinetics of deferiprone were observed following administration with food.</paragraph>
                                 </text>
                                 <effectiveTime value="20230831"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3631d351-468f-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The elimination half-life of deferiprone is approximately 2 hours.</paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                           <component>
                              <section>
                                 <id root="3631d351-4690-3512-e063-6394a90a81c0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Deferiprone is metabolized primarily by UGT1A6. The major metabolite of deferiprone is the 3-
 
  <content styleCode="italics">O</content>-glucuronide, which lacks iron binding capability.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230831"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3631d351-4691-3512-e063-6394a90a81c0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Following oral administration, 75% to 90% of the administered dose was recovered in urine (primarily as metabolite) in the first 24 hours.</paragraph>
                                 </text>
                                 <effectiveTime value="20230831"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3631d351-4692-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in the pharmacokinetics of deferiprone were observed based on sex, race/ethnicity, body weight, mild to severe (eGFR 15 to 89 mL/min/1.73 m
 
  <sup>2</sup>) renal impairment, or mild (Child Pugh Class A) to moderate (Child Pugh Class B) hepatic impairment. The effect of age, including geriatric or pediatric populations, end stage renal disease or severe (Child Pugh Class C) hepatic impairment on the pharmacokinetics of deferiprone is unknown.

 </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3631d351-4693-3512-e063-6394a90a81c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                           <component>
                              <section>
                                 <id root="3631d351-4694-3512-e063-6394a90a81c0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro Studies</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20230831"/>
                                 <component>
                                    <section>
                                       <id root="3631d351-4695-3512-e063-6394a90a81c0"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">UGTIA6 Inhibitors:</content>Phenylbutazone (UGT1A6 inhibitor) decreased glucuronidation of deferiprone by up to 78%.

 </paragraph>
                                       </text>
                                       <effectiveTime value="20230831"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="3631d351-4696-3512-e063-6394a90a81c0"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Polyvalent Cations:</content>Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc).

 </paragraph>
                                       </text>
                                       <effectiveTime value="20230831"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="3631d351-4697-3512-e063-6394a90a81c0"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230831"/>
               <component>
                  <section ID="S13.1">
                     <id root="3631d351-4698-3512-e063-6394a90a81c0"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been conducted with deferiprone. However, in view of the genotoxicity results, and the findings of mammary gland hyperplasia and mammary gland tumors in rats treated with deferiprone in the 52-week toxicology study, tumor formation in carcinogenicity studies must be regarded as likely.</paragraph>
                        <paragraph>Deferiprone was positive in a mouse lymphoma cell assay
 
  <content styleCode="italics">in vitro</content>. Deferiprone was clastogenic in an
 
  <content styleCode="italics">in vitro</content>chromosomal aberration test in mice and in a chromosomal aberration test in Chinese Hamster Ovary cells. Deferiprone given orally or intraperitoneally was clastogenic in a bone marrow micronucleus assay in non-iron-loaded mice. A micronucleus test was also positive when mice predosed with iron dextran were treated with deferiprone. Deferiprone was not mutagenic in the Ames bacterial reverse mutation test.

 </paragraph>
                        <paragraph>A fertility and early embryonic development study of deferiprone was conducted in rats. Sperm counts, motility and morphology were unaffected by treatment with deferiprone. There were no effects observed on male or female fertility or reproductive function at the highest dose which was 25% of the MRHD.</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="3631d351-4699-3512-e063-6394a90a81c0"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The following information is based on studies with deferiprone tablets (three times a day).</paragraph>
               </text>
               <effectiveTime value="20230831"/>
               <component>
                  <section ID="S14.1">
                     <id root="3631d351-469a-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Transfusional Iron Overload in Patients with Thalassemia Syndromes</title>
                     <text>
                        <paragraph>In a prospective, planned, pooled analysis of patients with thalassemia syndromes from several studies, the efficacy of deferiprone was assessed in transfusion-dependent iron overload patients in whom previous iron chelation therapy had failed or was considered inadequate due to poor tolerance. The main criterion for chelation failure was serum ferritin &gt; 2,500 mcg/L before treatment with deferiprone. Deferiprone therapy (35 to 99 mg/kg/day) was considered successful in individual patients who experienced a ≥ 20% decline in serum ferritin within one year of starting therapy.</paragraph>
                        <paragraph>Data from a total of 236 patients were analyzed. Of the 224 patients with thalassemia who received deferiprone monotherapy and were eligible for serum ferritin analysis, 105 (47%) were male and 119 (53%) were female. The mean age of these patients was 18.2 years (range 2 to 62; 91 patients were &lt;17).</paragraph>
                        <paragraph>For the patients in the analysis, the endpoint of at least a 20% reduction in serum ferritin was met in 50% (of 236 subjects), with a 95% confidence interval of 43% to 57%.</paragraph>
                        <paragraph>A small number of patients with thalassemia and iron overload were assessed by measuring the change in the number of milliseconds (ms) in the cardiac MRI T2* value before and after treatment with deferiprone for one year. There was an increase in cardiac MRI T2* from a mean at baseline of 11.8 ± 4.9 ms to a mean of 15.1 ± 7.0 ms after approximately one year of treatment. The clinical significance of this observation is not known.</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="3631d351-469b-3512-e063-6394a90a81c0"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20230831"/>
               <component>
                  <section>
                     <id root="3631d351-469c-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Deferiprone Tablets (three times a day), 1,000 mg</content>
                        </paragraph>
                        <paragraph>White, film-coated, oval shaped tablets; imprinted with "T" score "1 K" on one side and plain on the other. The tablets can be broken in half along the score line. They are provided in HDPE bottles.</paragraph>
                        <paragraph>1,000 mg film-coated tablets, 50 tablets</paragraph>
                        <paragraph>NDC 51672-4237-4</paragraph>
                        <paragraph>Keep the bottle tightly closed to protect from moisture.</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-469d-3512-e063-6394a90a81c0"/>
                           <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Store at 20°C to 25°C (68°F to 77°F)</content>; [see USP Controlled Room Temperature].

 </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3631d351-469e-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Deferiprone Tablets, 500 mg</content>
                        </paragraph>
                        <paragraph>White to pinkish-white, capsule-shaped tablets; scored on one side, engraved "T" on the left of the score line and "5" on the right and plain on the other side. They are provided in a 100 count HDPE bottle with a child-resistant cap.</paragraph>
                        <paragraph>500 mg tablets, 100 tablets</paragraph>
                        <paragraph>NDC 51672-4196-1</paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                     <component>
                        <section>
                           <id root="3631d351-469f-3512-e063-6394a90a81c0"/>
                           <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">Store at 20° to 25°C (68° to 77°F)</content>[see USP Controlled Room Temperature].

 </paragraph>
                           </text>
                           <effectiveTime value="20230831"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="3631d351-46a0-3512-e063-6394a90a81c0"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide)</paragraph>
               </text>
               <effectiveTime value="20230831"/>
               <component>
                  <section>
                     <id root="3631d351-46a1-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Instruct patients and their caregivers to store deferiprone at 68°F to 77°F (20°C to 25°C) [see USP Controlled Room Temperature].</item>
                           <item>
                              <content styleCode="underline">Deferiprone tablets (three times a day), 1,000 mg:</content>
                              <br/>  Store in the originally supplied bottle, closed tightly to protect from moisture. 
   <br/>  Advise patients to take the first dose of deferiprone in the morning, the second dose at midday, and the third dose in the evening. Clinical experience suggests that taking deferiprone with meals may reduce nausea.
 
  </item>
                           <item>
                              <content styleCode="underline">Deferiprone tablets, 500 mg:</content>
                              <br/>  Store in the originally supplied bottle, closed tightly to protect from moisture. 
   <br/>  Advise patients to take the first dose of deferiprone in the morning, the second dose at midday, and the third dose in the evening. Clinical experience suggests that taking deferiprone with meals may reduce nausea.
 
  </item>
                           <item>If a dose of this medicine has been missed, take it as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to the regular dosing schedule. Do not catch-up or double doses.</item>
                           <item>Inform patients of the risks of developing agranulocytosis and the need for regular blood testing before and during their treatment to monitor for decreases in their ANC. Instruct them to immediately interrupt therapy and report to their physician if they experience any symptoms of infection such as fever, sore throat or flu-like symptoms
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>and
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>in order to check their ANC within 24 hours. Advise them if they are unable to reach their physician, seek care from another provider so as not to delay medical care.
 
  </item>
                           <item>Inform patients of the risk of abnormal liver transaminases and the need for regular blood testing before and during their treatment to monitor for increases in ALT
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>and
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>.
 
  </item>
                           <item>Inform patients of the risk of zinc deficiency and the need for regular blood testing before and during their treatment to monitor for reductions in zinc
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>and
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>.
 
  </item>
                           <item>Advise patients to contact their physician in the event of overdose.</item>
                           <item>Inform patients that their urine might show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex. This is a very common sign of the desired effect, and it is not harmful.</item>
                        </list>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3631d351-46a2-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>and
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]
 
  </content>. Advise female patients of reproductive potential to use effective contraception during treatment with deferiprone and for at least six months after the last dose
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>,
  
   <linkHtml href="#S8.3">8.3)</linkHtml>]
 
  </content>. Advise males with female partners of reproductive potential to use effective contraception during treatment with deferiprone and for at least three months after the last dose
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>and
  
   <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3631d351-46a3-3512-e063-6394a90a81c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise females not to breastfeed during treatment with deferiprone and for at least 2 weeks after the last dose
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230831"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_357d1f16-01b1-7f46-e063-6294a90abc54">
               <id root="3631d351-46a4-3512-e063-6394a90a81c0"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761 
  <br/>  Dist. by:
 
  <content styleCode="bold">Sun Pharmaceutical Industries, Inc.,</content>Cranbury, NJ 08512

 </paragraph>
                  <paragraph>Revised: April 2025 
  <br/>  5230551-0425-03
 </paragraph>
               </text>
               <effectiveTime value="20240101"/>
            </section>
         </component>
         <component>
            <section ID="MEDGUIDE">
               <id root="3631d351-46a5-3512-e063-6394a90a81c0"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Dispense with Medication Guide available at: https://www.sunpharma.com/usa/products</content>
                     </content>
                  </paragraph>
                  <table width="100%">
                     <col align="left" valign="top" width="32%"/>
                     <col align="left" valign="top" width="18%"/>
                     <col align="left" valign="top" width="18%"/>
                     <col align="left" valign="top" width="32%"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="4">This Medication Guide has been approved by the U.S. Food and Drug Administration.</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td align="center" colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Medication Guide 
      <br/>  Deferiprone (de-fer-ip-rone) Tablets
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is the most important information I should know about deferiprone tablets? 
      <br/>  Deferiprone tablets can cause serious side effects
     </content>, including a very low white blood cell count. One type of white blood cell that is important for fighting infections is called a neutrophil. If your neutrophil count is low (neutropenia), you may be at risk of developing a serious infection that can lead to death. Neutropenia is common with deferiprone tablets and can become severe in some people. Severe neutropenia is known as agranulocytosis. If you develop agranulocytosis, you will be at risk of developing serious infections that can lead to death. 
     <br/>  Your healthcare provider will do a blood test before you start deferiprone tablets and regularly during treatment to check your neutrophil count. If you develop neutropenia, your healthcare provider should check your blood counts every day until your white blood cell count improves. Your healthcare provider may temporarily stop treatment with deferiprone tablets if you develop neutropenia or infection. 
     <br/>
                              <content styleCode="bold">Stop taking deferiprone tablets and call your healthcare provider or get medical help right away if you develop any of these symptoms of infection:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>fever</item>
                                 <item>sore throat or mouth sores</item>
                                 <item>flu-like symptoms</item>
                                 <item>chills and severe shaking</item>
                              </list>
                              <content styleCode="bold">It is important for you to have your white blood cell count checked within 24 hours of developing symptoms of an infection to see if you have severe neutropenia (agranulocytosis). Do not delay getting medical care if you are unable to reach your healthcare provider.</content>
                              <br/>  See
    
     <content styleCode="bold">"
     
      <linkHtml href="#Effects">What are the possible side effects of deferiprone tablets?</linkHtml>"
    
     </content>for more information about side effects.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is deferiprone?</content>
                              <br/>  Deferiprone is a prescription medicine used to treat iron overload from blood transfusions in adults with thalassemia syndromes when current iron removal (chelation) therapy does not work well enough. 
     <br/>  It is not known if deferiprone tablets is safe and effective to treat iron overload due to blood transfusions:
    
     <list listType="unordered" styleCode="Disc">
                                 <item>in people with myelodysplastic syndrome or Diamond Blackfan anemia</item>
                                 <item>in children less than 8 years of age</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Do not take deferiprone tablets if you are allergic to deferiprone or any of the ingredients in deferiprone tablets.</content>See the end of this Medication Guide for a complete list of ingredients in deferiprone tablets.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before taking deferiprone tablets, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have liver problems</item>
                                 <item>are pregnant or plan to become pregnant. Deferiprone tablets can harm your unborn baby. You should avoid becoming pregnant during treatment with deferiprone tablets. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with deferiprone tablets. 
       <br/>
                                    <content styleCode="bold">Females who are able to become pregnant:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider should do a pregnancy test before you start treatment with deferiprone tablets.</item>
                                       <item>You should use effective birth control during treatment with deferiprone tablets and for at least 6 months after the last dose.</item>
                                    </list>
                                    <content styleCode="bold">Males with female partners who are able to become pregnant:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>You should use effective birth control during treatment with deferiprone tablets and for at least 3 months after the last dose.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if deferiprone passes into your breast milk. Do not breastfeed during treatment with deferiprone tablets and for at least 2 weeks after the last dose.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content>including prescription and over-the-counter medicines, vitamins and herbal supplements.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I take deferiprone tablets?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take deferiprone tablets exactly as your healthcare provider tells you.</item>
                                 <item>Your healthcare provider will prescribe deferiprone tablets based on your body weight.</item>
                                 <item>Your healthcare provider will check your body iron level during treatment with deferiprone tablets and may change your dose if needed. Your healthcare provider may also change your dose of deferiprone tablets if you have certain side effects. Do not change your dose of deferiprone tablets unless your healthcare provider tells you to.</item>
                                 <item>
                                    <content styleCode="bold">There are 2 types of deferiprone tablets. Be sure you are taking the correct tablet and ask your healthcare provider if unsure.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Deferiprone Tablets 
      <br/>  1,000 mg 
      <br/>  3 times each day
     </content>
                           </td>
                           <td align="center" colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Deferiprone Tablets 
      <br/>  500 mg 
      <br/>  3 times each day
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td align="left" colspan="2" styleCode="Lrule Rrule">Take your first dose in the morning, the second dose at midday, and the third dose in the evening.</td>
                           <td align="left" colspan="2" styleCode="Lrule Rrule">Take your first dose in the morning, the second dose at mid-day, and the third dose in the evening.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Taking deferiprone tablets with meals may help reduce nausea.</item>
                                 <item>
                                    <content styleCode="bold">If you must take a medicine to treat indigestion (antacid), or supplements that contain iron, aluminum, or zinc during treatment with deferiprone tablets, allow at least 4 hours between taking deferiprone tablets and these products.</content>
                                 </item>
                                 <item>If you take too much deferiprone tablets, call your healthcare provider.</item>
                                 <item>If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and then continue with your regular schedule. Do not try to catch-up or take 2 doses at the same time to make up for a missed dose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of deferiprone tablets? 
      <br/>  Deferiprone tablets can cause serious side effects, including:
     </content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">See "
       
        <linkHtml href="#Important">What is the most important information I should know about deferiprone tablets?</linkHtml>"
      
       </content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased liver enzyme levels in your blood.</content>Your healthcare provider should do blood tests to check your liver function before you start and then monthly during treatment with deferiprone tablets. Your healthcare provider may temporarily stop treatment with deferiprone tablets if you develop increased liver enzyme levels and they continue to be increased.
     
      </item>
                                 <item>
                                    <content styleCode="bold">Decreased levels of zinc in your blood.</content>Your healthcare provider will do blood tests to check your zinc levels before you start and during treatment with deferiprone tablets, and may prescribe a zinc supplement for you if your zinc levels are low.
     
      </item>
                              </list>
                              <content styleCode="bold">The most common side effects of deferiprone tablets in people with thalassemia include:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>nausea</item>
                                 <item>vomiting</item>
                                 <item>stomach-area (abdominal) pain</item>
                                 <item>joint pain</item>
                                 <item>abnormal liver function tests</item>
                                 <item>low white blood cells</item>
                              </list>Deferiprone tablets may cause a change in urine color to reddish-brown. This is not harmful and is expected during treatment with deferiprone tablets. 
     <br/>  These are not all of the possible side effects of deferiprone tablets. 
     <br/>  Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store deferiprone tablets?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Deferiprone Tablets 
      <br/>  1,000 mg 
      <br/>  3 times each day
     </content>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule">
                              <content styleCode="bold">Deferiprone Tablets 
      <br/>  500 mg 
      <br/>  3 times each day
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Rrule Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                                 <item>Store in the original bottle and tightly closed to protect from moisture.</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Keep deferiprone tablets and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of deferiprone tablets.</content>
                              <br/>  Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use deferiprone tablets for a condition for which it was not prescribed. Do not give deferiprone tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about deferiprone tablets that is written for health professionals.
   
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in deferiprone tablets?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Deferiprone Tablets 
      <br/>  1,000 mg 
      <br/>  3 times each day
     </content>
                           </td>
                           <td align="center" colspan="2" styleCode="Rrule">
                              <content styleCode="bold">Deferiprone Tablets 
      <br/>  500 mg 
      <br/>  3 times each day
     </content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Active ingredient:</content>deferiprone 
     <br/>
                              <content styleCode="bold">Inactive ingredients:</content>Tablet core: crospovidone, magnesium stearate and methylcellulose. Coating: copovidone, hypromellose, medium chain triglycerides, polydextrose, polyethylene glycol and titanium dioxide.
   
    </td>
                           <td colspan="2" styleCode="Rrule">
                              <content styleCode="bold">Active ingredient:</content>deferiprone 
     <br/>
                              <content styleCode="bold">Inactive ingredients:</content>Tablet core: crospovidone, magnesium stearate and methylcellulose.
   
    </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">Mfd. by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761 
     <br/>  Dist. by:
    
     <content styleCode="bold">Sun Pharmaceutical Industries, Inc.,</content>Cranbury, NJ 08512 
     <br/>
                              <br/>  For more information, call 1-866-923-4914 or visit https://www.sunpharma.com/usa/products
   
    </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="italics">Pediatric use information is approved for Chiesi USA, Inc.'s FERRIPROX® (deferiprone) tablets. However, due to Chiesi USA, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.</content>
                  </paragraph>
                  <paragraph>Revised: April 2025</paragraph>
                  <paragraph>5230551-0425-03</paragraph>
               </text>
               <effectiveTime value="20240101"/>
            </section>
         </component>
         <component>
            <section ID="id_link_35968eae-c7f6-0e23-e063-6294a90a3d6b">
               <id root="3631d351-46a6-3512-e063-6394a90a81c0"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions, Agranulocytosis and Neutropenia (5.1) 3/2025</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="id_link_11b37964-61fc-76ec-e063-6294a90a500e">
               <id root="36326339-61c2-b0f5-e063-6294a90a0131"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_11b37f48-b5b0-7d88-e063-6394a90a9704"/>NDC 51672-4196-1
  <br/>
100 Tablets
 </paragraph>
                  <paragraph>Deferiprone
  <br/>
Tablets 500 mg
 </paragraph>
                  <paragraph>PHARMACIST: Dispense Medication Guide to each patient.
  <br/>
Print Medication Guides at: www.taro.com
 </paragraph>
                  <paragraph>TARO</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_36322f20-c452-5e47-e063-6294a90aec22"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20230831"/>
               <component>
                  <observationMedia ID="img_11b37f48-b5b0-7d88-e063-6394a90a9704">
                     <text>deferiprone-02</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="500 mg label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_36322f20-c452-5e47-e063-6294a90aec22">
                     <text>500 mg SUN label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="500-mg-SUN-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_1294f59c-df3e-a76f-e063-6294a90a8628">
               <id root="36323efa-6263-81c6-e063-6294a90a4bcd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1,000 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 51672-4237-4
  <br/>
50 Tablets
 </paragraph>
                  <paragraph>THREE-TIMES-A-DAY</paragraph>
                  <paragraph>Deferiprone
  <br/>
Tablets 1,000 mg
 </paragraph>
                  <paragraph>Attention Pharmacist: Dispense the accompanying
  <br/>
Medication Guide to each patient.
 </paragraph>
                  <paragraph>TARO</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_17deae31-fcd8-75bd-e063-6394a90ae32c"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3632458e-14c2-6d2a-e063-6294a90a1807"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20230831"/>
               <component>
                  <observationMedia ID="img_17deae31-fcd8-75bd-e063-6394a90ae32c">
                     <text>DEFERIPRONE-03</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="RX523050601L50-TARO19A.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="img_3632458e-14c2-6d2a-e063-6294a90a1807">
                     <text>1000 mg SUN label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="1000-mg-SUN-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>